BRAF and melanoma: Its modified analog compound 9b (Figure 2, PES-Cl) was antiproliferative against a panel of BRAF-V600E mutant melanoma (IC50 values between 2–5 μM, while inactive against melanocytes) and showed higher antiproliferative activity than compound 9a against SkBr3 breast carcinoma, FaDu head and neck squamous cell carcinoma, and H1299 lung adenocarcinoma cells [64].